Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Let's see if Johnson & Johnson (JNJ) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Should Value Investors Pick Johnson & Johnson (JNJ) Stock?

Scientists have revealed data from their final analysis of Johnson & Johnson's JNJ COVID-19 Phase 3 study, showing the vaccine may be even less effective in the longer term. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Final Analysis Show Johnson & Johnson's COVID-19 Offers Only 52.9% Protection

Domino's Pizza

Shopify

Some of these high-conviction holdings have taken a beating recently, but that doesn't mean these investors have any plans to sell.

3 Investors Share the Largest Holdings in Their Stock Portfolios

Looking at blue-chip stocks, JNJ presents as the best value buying by a long way, headlining with a P/E valuation discount of 41.9% to it's peers by market cap. If your portfolio could use more stability and dividend income as the market shifts from growth to value stocks, JNJ has a lot going for it.

Give Your Portfolio A Blue-Chip Dividend Booster Shot With Johnson & Johnson

NEW BRUNSWICK, N.J., Feb. 9, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 43rd Annual Institutional Investors Conference on Tuesday, March 8 th.

Johnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference

Johnson & Johnson (NYSE:JNJ) (J&J) has temporarily halted production of Covid vaccines at a plant in Europe, according to reports overnight. The Dutch plant should be producing vaccines again in a few months, the report in the New York Times said, but currently the facility was making a new vaccine against a different virus.

Johnson & Johnson switches Dutch plant away from Covid vaccine - report

The company's one-dose COVID-19 vaccine has been the only option in some parts of the world.

Johnson & Johnson reportedly pauses COVID vaccine production, raising vaccine access concerns

The only Johnson & Johnson facility making usable batches of the company's Covid vaccine has temporarily halted its production, The New York Times reported.

Johnson & Johnson plant pauses Covid vaccine production, report says

Production at a key Covid-19 vaccine plant has been paused though many African nations continue to report low vaccine supplies.

Johnson & Johnson Reportedly Pauses Covid Vaccine Production Despite Sharp Need In Developing Countries

Johnson & Johnson  JNJ quietly shut down the only plant making usable batches of its COVID-19 vaccine, the New York Times reported, citing people familiar with the decision. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Johnson & Johnson Halts Production Of Its COVID-19 Vaccine: NYT

The Times reported that the company shut down the only plant making usable vaccine batches in the Netherlands late last year.

Johnson & Johnson quietly halted production of its COVID-19 vaccines: NYT

AbbVie

Inmode Ltd

Whether you're looking for growth or big dividends, the healthcare sector's got deals galore.

3 Top Healthcare Stocks to Buy for February

(Reuters) -Johnson & Johnson late last year quietly shut down the only plant making usable batches of its COVID-19 vaccine, the New York Times reported, citing people familiar with the decision.

J&J pauses production of its COVID-19 vaccine - NYT

NEW BRUNSWICK, N.J., Feb. 7, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 42nd Annual Health Care Virtual Conference on Monday, March 7 th.

Johnson & Johnson to Participate in the Cowen 42nd Annual Health Care Virtual Conference

BioNTech SE

Moderna

Novavax

Pfizer

Some of last year's superstars have lost more than 30% since December.

Is it Too Late to Buy Vaccine Stocks?

Move to hold shareholder vote follows withdrawal of product in US and Canada and lawsuits alleging link to cancer cases

Johnson & Johnson faces push to force global ban on talc baby powder sales

Johnson & Johnson tried to get a U.S. judge to block Reuters from publishing a story based on what it said were confidential company documents about the healthcare giant's legal maneuvers to fight lawsuits claiming its Baby Powder caused cancer.

J&J tried to get federal judge to block publication of Reuters story

Johnson & Johnson created a plan last year to limit the financial bleeding from billions of dollars in jury awards to plaintiffs who alleged the company's Baby Powder and other talc products caused deadly cancers. The healthcare and consumer-goods giant assigned more than 30 staffers to “Project Plato.

Special Report-Inside J&J's secret plan to cap litigation payouts to cancer victims

Mersana Therapeutics

Mersana Therapeutics Inc MRSN has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ, to discover antibody-drug conjugates (ADCs) for three targets. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets

Its profit last quarter more than doubled in size, but what was behind that impressive result?

Johnson & Johnson's Q4: Looking Behind the Numbers

The pharmaceutical segment continues to be J&J's biggest growth driver.

Here's What to Like About Johnson & Johnson's Q4 Update

Johnson & Johnson JNJ and the three U.S. drug distributors agreed to pay about $590 million to resolve claims from over 400 Native American tribes to settle lawsuits over the opioid epidemic. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Johnson & Johnson, Distributors Reach $590M Opioid Settlement For Tribe Claims: Report

Easterly Government Properties

Dollar General

These stocks offer stability during turbulent times.

3 Stocks to Buy Now If You're Anxious About the Stock Market

J & J Snack Foods

J&J Snack Foods Corp.'s (JJSF) CEO Dan Fachner On Q1 2022 Results - Earnings Call Transcript

The three largest U.S. drug distributors and drugmaker Johnson & Johnson have agreed to pay $590 million to resolve claims by Native American tribes that the companies fueled an opioid epidemic in their communities, according to court filings.

News for Johnson & Johnson Stock (JNJ)